Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease (DECODE)

21 febbraio 2017 aggiornato da: University of Surrey

DNA Damage and Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease

The purpose of this study is:

  1. To examine the association between stable and unstable coronary artery disease (CAD) with markers of DNA damage and repair,
  2. To examine the association between plaque morphology as assessed by frequency-domain optical coherence tomography (FD-OCT) and markers of DNA damage and repair in order to identify potential markers of plaque instability,
  3. To examine the association between markers of DNA damage and repair and major adverse cardiovascular events defined as death, MI and unplanned percutaneous or surgical revascularization,

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Hypotheses ----------------

We hypothesise that defective DNA damage response is an important aetiological factor in the development of CAD, underlying CAD severity and development. If this hypothesis is true, then we predict that:

  1. There is differential expression of markers of DNA damage and repair in patients with stable angina, a model of stable CAD, and patients with non ST-elevation myocardial infarction (NSTEMI), a model of unstable CAD.
  2. Differential expression of markers of DNA damage and repair correlate with plaque morphology and stability as defined by FD-OCT,
  3. Markers of DNA damage and repair can serve as distinguishing markers of stable and unstable CAD,

    Methodology

    ------------------

    Study Population:

    Patients presenting with stable angina undergoing percutaneous revascularization at Ashford and St. Peter's Hospitals Foundation Trust will be prospectively enrolled. Data regarding demographic, clinical, and procedural characteristics of patients will be collected by the Ashford and St. Peter's Hospitals Foundation Trust research personnel and entered into a secure, encrypted, dedicated database.

    Pre-defined clinical and angiographic inclusion and exclusion criteria will be met as per the DECODE study protocol.

    FD-OCT (St. Jude Medical ILUMIEN OCT System) will be performed in all the three main epicardial coronary arteries prior to target vessel PCI after administration of glyceryl trinitrate. Data will be acquired in a designated, secure compute and sent to a corelab for analysis. Quantitative measurements will include endoluminal area, plaque area, as well as plaque parameters including thin- capped fibroatheromas (TCFA), fibrous tissue, lipid core and calcium. TCFA will be defined by lipid-rich plaque with cap thickness ≤ 65μm.

    Culprit lesions will be defined according to electrocardiographic criteria (ST-segment shift or T-wave inversion) and angiographic appearances (luminal irregularities consistent with lesion ulceration, filling defect(s) consistent with thrombus, or point of angiographic maximal stenosis) in patients with NSTEMI and angiographic stenosis ≥ 70% in patients with stable angina not responding to at least two anti-anginal medications.

    Blood will be drawn immediately prior to percutaneous coronary intervention. In addition to routine haematological and biochemical parameters (complete blood count, white cell count, platelet count, creatinine, urea, sodium, potassium, cholesterol, glucose, troponine I, creatinine phosphokinase, liver function tests and clotting screen) one additional blood sample will be taken and separated into plasma and serum. Polymorphonuclear leukocytes will be used for measurements of DNA damage and repair proteins.

    Clinical follow-up will occur at 30-day and 12-month from enrolment by telephone interview and clinic visits. A repeat blood sample will be taken for analysis of DNA damage and repair proteins.

    DNA Damage

    ------------------

    DNA damage will be analysed by measuring DNA strand breaks in cell pellets using the comet assay. Serum oxidised purines will also be measured using an ELISA based assay. The transcriptional activation of DNA damage proteins will be assessed by real time PCR. For this, RNA will be isolated using a Roche High Pure Isolation kit. The RT2 First Strand Kit (SABioscience) will be utilised for reverse transcription of total RNA. Automated PCR will be set up and the raw data will be normalised using the average cycle threshold (ct) value of four housekeeping genes (B2M, RPL13A, GAPDH, and ACTB).

    Whether differential gene expression leads to differential protein expression will be determined by Western blotting. Moreover, the phosphorylation status of DNA damage proteins will also be assessed.

    DNA repair activity will also be assessed for several DNA repair enzymes important for the repair of base damage generated by reactive oxygen and nitrogen species. DNA repair activity will be measured by using in-vitro oligonucleotide-based cleavage assays.

    Finally, we will then correlate measures of DNA damage and repair with patient presentation (stable angina vs. NSTEMI), MACE, and FD-OCT derived parameters including the number of TCFA, plaque volume and percentage of plaque components.

    Statistical analysis

    -------------------------

    Statistical analysis will be performed using SAS version 8.2 (SAS institute Inc., Cary, North Carolina). Biomarker parameters will be tested for an association with patient presentation (stable angina vs. NSTEMI) and MACE using a log-rank test. OCT derived parameters will be tested for an association with biomarkers using univariate Cox proportional hazard regression. Parameters with a significance level of ≤0.1 on univariate analysis will undergo multivariate Cox proportional hazard analysis. A p value <0.05 will be considered statistically significant.

    The recruitment period is anticipated to last 15-18 months, with data collation and interpretation throughout recruitment and analysis anticipated to be complete by 24 months.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

126

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Surrey
      • Chertsey, Surrey, Regno Unito, KT16 0PZ
        • Ashford and St. Peter's Hospital
      • Guildford, Surrey, Regno Unito, GU2 7XH
        • University of Surrey

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Patients presenting with stable angina (n=50) or NSTEMI (n=50) undergoing percutaneous revascularization at Ashford and St. Peter's Hospitals Foundation Trust will be prospectively enrolled. Data regarding demographic, clinical, and procedural characteristics of patients will be collected by the Ashford and St. Peter's Hospitals Foundation Trust research personnel and entered into a secure, dedicated database. Results will be compared to age and sex matched controls

Descrizione

Inclusion Criteria

-----------------------

Clinical:

  1. Age ≥ 18 years
  2. Stable angina not responding to at least two anti-anginal medications (beta blockers, calcium channel antagonists, long acting nitrate, Nicorandil, Ivabradine, or Ranolazine), or NSTEMI.
  3. Patient is able to provide written, informed consent and is able to follow protocol procedures.

Angiographic:

1. Successful and uncomplicated percutaneous coronary intervention (PCI) performed in the major epicardial coronary arteries.

NB: Successful PCI is defined as residual diameter stenosis < 5% in all treated lesions with thrombolysis in myocardial infarction (TIMI)-3 flow (defined as normal flow which fills the distal coronary bed completely), absence of intraprocedural chest pain or ST-segment changes lasting > 10 minutes, persistent vessel closure, no re-flow, perforation, dissection or requirement for cardiopulmonary resuscitation, defibrillation, pacemaker or intra-aortic balloon implantation.

Exclusion Criteria:

------------------------

Clinical:

  1. Presentation with ST-elevation MI (STEMI),
  2. Decompensated heart failure, hypotension, shock, refractory ventricular tachycardia, acute conduction disorders, left ventricular ejection fraction ≤ 30%,
  3. Prior coronary revascularization,
  4. Any form of surgery up to three months prior to enrolment,
  5. Active inflammatory disorders,
  6. Bleeding diathesis,
  7. Known allergy, hypersensitivity, or contraindication to aspirin, heparin, or thienopyridines,
  8. Life expectancy less than 1 year,
  9. Diabetes mellitus.

Angiographic:

  1. Left main coronary artery stenosis ≥ 50%,
  2. Coronary artery bypass surgery planned within one year of the PCI,
  3. Anatomical conditions precluding three-vessel FD-OCT (significant tortuosity, severe calcification, chronic total occlusion).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Stable angina patients

Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.

Clinical and angiographic exclusion criteria as stated in the study protocol.

NSTEMI patients

Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :

Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:

  • Symptoms of ischaemia
  • Development of pathologic Q waves in the electrocardiogram (ECG)
  • New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.
  • Identification of an intracoronary thrombus by angiography.
  • Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Difference in DNA ligase activity in peripheral blood mononuclear cells of patients with stable angina and non-ST-elevation myocardial infarction
Lasso di tempo: 18 months
DNA ligase (DNA repair enzyme) activity measured using units per well, in peripheral mononuclear cells between stable and NSTEMI patients undergoing percutaneous coronary intervention.
18 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Plaque fibrous cap thickness and its association with major adverse cardiovascular events (MACE)
Lasso di tempo: 18 months
Examine the correlation between markers of DNA damage with plaque morphology and cap thickness, measured in micrometres, as assessed with optical coherence tomography and major adverse cardiac events defined as a composite of death, MI and target lesion revascularisation.
18 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 settembre 2014

Completamento primario (Effettivo)

1 ottobre 2016

Completamento dello studio (Effettivo)

1 ottobre 2016

Date di iscrizione allo studio

Primo inviato

28 ottobre 2014

Primo inviato che soddisfa i criteri di controllo qualità

6 gennaio 2015

Primo Inserito (Stima)

9 gennaio 2015

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 febbraio 2017

Ultimo aggiornamento inviato che soddisfa i criteri QC

21 febbraio 2017

Ultimo verificato

1 febbraio 2017

Maggiori informazioni

Termini relativi a questo studio

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi